Synlogic (SYBX) Tops Q3 EPS by 9c

Synlogic (NASDAQ: SYBX) reported Q3 EPS of ($0.39), $0.09 better than the analyst estimate of ($0.48).

“We are making good progress towards our goal of evaluating the breadth of therapeutic applications of our Synthetic Biotic platform. Notably, the recent initiation of the first clinical trial of a Synthetic Biotic medicine for the treatment of cancer represents a significant step for Synlogic,” said Aoife Brennan, M.B., B.Ch., Synlogic’s president and chief executive officer. “We also continue to advance our SYNB1618 program for the treatment of phenylketonuria in an ongoing bridging study to evaluate the tolerability and activity of a solid oral formulation, and we look forward to sharing those data and our plans for the next steps in this program.”

For earnings history and earnings-related data on Synlogic (SYBX) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity